Ivermectin and mebendazole are two well-established antiparasitic agents that have been widely studied for their effectiveness against a broad range of parasitic infections. Ivermectin works by binding to glutamate-gated chloride channels in parasites, leading to paralysis and death, while mebendazole disrupts microtubule formation by inhibiting tubulin polymerization, ultimately impairing glucose uptake and energy production in parasitic organisms. When combined, these compounds offer a complementary mechanism of action, targeting parasites through distinct biological pathways. Emerging research has also explored their potential roles beyond traditional antiparasitic use, including investigations into antiviral and cellular-modulating properties, though these applications are still under scientific evaluation.